Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | THPO | P40225 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | APEX1 | P27695 | 1/20 | 0.32 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14984981 | 1.00 | ALDH1A1 (0.35) | ALDH1A1TSHRCHRNB2CHRNB4CHRNA4 | |
| SCHEMBL14984976 | 1.00 | ALDH1A1 (0.35) | ALDH1A1TSHRCHRNB2CHRNB4CHRNA4 | |
| SCHEMBL22041631 | 0.82 | ALDH1A1 (0.32) | ALDH1A1TSHRCHRNB2CHRNB4CHRNA4 | |
| SCHEMBL888942 | 0.80 | DPP4 (0.31) | DPP4 | |
| SCHEMBL21228068 | 0.79 | CHRNB2 (0.37) | ALDH1A1TSHRCHRNB2CHRNB4CHRNA4 | |
| SCHEMBL21228065 | 0.79 | CHRNB2 (0.37) | ALDH1A1TSHRCHRNB2CHRNB4CHRNA4 | |
| SCHEMBL21228294 | 0.79 | CHRNB2 (0.37) | ALDH1A1TSHRCHRNB2CHRNB4CHRNA4 | |
| SCHEMBL3656233 | 0.77 | DPP4 (0.32) | DPP4 | |
| SCHEMBL18909888 | 0.77 | DPP4 (0.32) | DPP4 | |
| SCHEMBL18907366 | 0.77 | DPP4 (0.32) | DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11130769-B2 | Spiro-sulfonamide derivatives as inhibitors of myeloid cell leukemia-1 (MCL-1) protein | PRELUDE THERAPEUTICS, INCORPORATED (US) | 2021-09-28 | — | — | US | disclosed |
| CN-107849362-B | Resin composition for display substrate, heat-resistant resin film using same, organic EL display substrate, and method for producing organic EL display | 东丽株式会社 | 2020-09-15 | — | — | CN | disclosed |
| US-20200207915-A1 | RESIN COMPOSITION, METHOD OF PRODUCING RESIN FILM, AND METHOD OF PRODUCING ELECTRONIC DEVICE | TORAY INDUSTRIES, INC. (JP) | 2020-07-02 | — | — | US | disclosed |
| CN-108431135-B | Resin composition, method for producing resin film, and method for producing electronic device | 东丽株式会社 | 2020-06-23 | — | — | CN | disclosed |
| US-20200157405-A1 | Oil Well Cement Settlement Stabilizer for High-Temperature Cementing of Oil and Gas Wells and Preparation Method Thereof, and Cement Slurry | CHINA UNIVERSITY OF PETROLEUM (EAST CHINA) (CN) | 2020-05-21 | — | — | US | disclosed |
| US-10655048-B1 | Oil well cement settlement stabilizer for high-temperature cementing of oil and gas wells and preparation method thereof, and cement slurry | CHINA UNIVERSITY OF PETROLEUM (EAST CHINA) (CN) | 2020-05-19 | — | — | US | disclosed |
| US-20200148705-A1 | Spiro-Sulfonamide Derivatives As Inhibitors Of Myeloid Cell Leukemia-1 (MCL-1) Protein | PRELUDE THERAPEUTICS, INCORPORATED | 2020-05-14 | — | — | US | disclosed |
| CN-111051432-A | Resin composition, method for producing resin film, and method for producing electronic device | 东丽株式会社 | 2020-04-21 | — | — | CN | disclosed |
| US-10590306-B2 | Resin composition for display substrate, and heat-resistant resin film, organic EL display substrate, and method for manufacturing organic EL display using same | TORAY INDUSTRIES, INC. (JP) | 2020-03-17 | — | — | US | disclosed |
| US-20190055428-A1 | RESIN COMPOSITION FOR DISPLAY SUBSTRATE, AND HEAT-RESISTANT RESIN FILM, ORGANIC EL DISPLAY SUBSTRATE, AND METHOD FOR MANUFACTURING ORGANIC EL DISPLAY USING SAME | TORAY INDUSTRIES, INC. (JP) | 2019-02-21 | — | — | US | disclosed |
| US-7888363-B2 | 1-Cyclopentyl-3-methyl-2-(2-pyridyl)indole-5-amino/thio/carbonyl derivatives; hepatitis C virus infection; synergistic with another inhibitor of HCV polymerase or immunomodulatory agent such as interferons | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-02-15 | — | — | US | disclosed |
| US-7713681-B2 | Method for preparation of lithographic printing plate | FUJIFILM CORPORATION (JP) | 2010-05-11 | — | — | US | disclosed |
| US-7598244-B2 | [1,2,4]triazolo[1,5,a]pyrimidin-2-ylurea derivative and use thereof | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2009-10-06 | — | — | US | disclosed |
| US-7598244-B2 | [1,2,4]triazolo[1,5,a]pyrimidin-2-ylurea derivative and use thereof | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2009-10-06 | — | — | US | disclosed |
| US-20080160451-A1 | METHOD FOR PREPARATION OF LITHOGRAPHIC PRINTING PLATE | FUJIFILM CORPORATION (JP) | 2008-07-03 | — | — | US | disclosed |
| US-20070142380-A1 | Viral Polymerase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-06-21 | — | — | US | disclosed |
| US-7223785-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-29 | — | — | US | disclosed |
| US-7223785-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-29 | — | — | US | disclosed |
| US-20070010515-A1 | [1,2,4] Triazolo [1,5, a] pyrimidin-2-ylurea derivative and use thereof | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2007-01-11 | — | — | US | disclosed |
| US-20070010515-A1 | [1,2,4] Triazolo [1,5, a] pyrimidin-2-ylurea derivative and use thereof | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010515-A1 | [1,2,4] Triazolo [1,5, a] pyrimidin-2-ylurea derivative and use thereof | HLA-C, TPMT, TAP1 | ALDH1A1 208/4885TSHR 3257/4885CHRNB2 4816/4885 |
| US-11130769-B2 | Spiro-sulfonamide derivatives as inhibitors of myeloid cell leukemia-1 (MCL-1) protein | MCL1, BCL2A1, BCL2L1 | ALDH1A1 475/4885TSHR 4554/4885CHRNB2 4868/4885 |
| US-20070142380-A1 | Viral Polymerase Inhibitors | POLM, POLR2H, POLR2A | ALDH1A1 1556/4885TSHR 3904/4885CHRNB2 4297/4885 |
| US-20200148705-A1 | Spiro-Sulfonamide Derivatives As Inhibitors Of Myeloid Cell Leukemia-1 (MCL-1) Protein | MCL1, BCL2A1, BCL2L1 | ALDH1A1 475/4885TSHR 4554/4885CHRNB2 4868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.